Navigation Links
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Date:5/30/2008

Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses, and we will not receive any of the expected revenues relative to ABthrax. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Amgen (NASDAQ: AMGN ) ... 2014. Key results include: , Total revenues increased ... sales growth driven by strong performance across the portfolio, ... Prolia ® (denosumab) and XGEVA ® (denosumab). ... driven by higher revenues and a significant increase in ...
(Date:7/29/2014)... July 29, 2014 Regado Biosciences, Inc. (Nasdaq: ... the Phase 3 clinical development of Revolixys™ Kit (previously ... system, today announced that it will hold a conference ... 2014, at 8:30 a.m. EDT to discuss its second ... Interested participants and investors may access the conference call ...
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... 27, 2011 A milestone in lupus research was met this ... Research (ALR) held its 8th annual New York City Walk ... Park was matched by the enthusiasm of the nearly 3000 walkers ... by NYC master of ceremonies, My9 news anchor Brenda Blackmon, ALR ...
... 27, 2011   FHSSA counts its partnership initiative ... known as the Foundation for Hospices in Sub-Saharan ... between US hospice programs and organizations providing care ... assistance, support and friendship.  They are working collaboratively ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2FHSSA Launches New Campaign to Partner US Hospices with Programs in Sub-Saharan Africa 2
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps Treatment ... he cured his condition with the use of this method ... his experience. , He claimed that he was able ... 4 days. Since his method turned out being so effective, ... the world. , The Nasal Polyps Treatment Miracle program ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip reveals in ... by a holistic nutritional and functional medicine practitioner, who spent ... this problem. , Karen suffered from leaky gut, too, so ... to develop this unique treatment. , Karen Brimeyer decided ... sufferers from all around the world. The author of the ...
(Date:7/29/2014)... 2014 Parker Waichman LLP, a national ... injured by defective drugs and medical devices, reports that ... in Canada who allege that they were never warned ... the low testosterone injection Delatestryl (Court File No. 3704CP/14). ... the Ontario Superior Court of Justice. , “Testosterone lawsuits ...
(Date:7/29/2014)... 2014 Daily Gossip reveals in its review ... system that will permanently eliminate all the symptoms associated to ... treatment will banish symptoms such as mild hearing loss, as ... by patients will be gone forever. , The method will ... author of this program says that at the end of ...
(Date:7/29/2014)... young children to embrace a more healthful diet? ... them. Doing so will actually make them think it ... and caregivers who are struggling to get children to ... food without saying anything about it, or (if credible) ... authors Michal Maimaran, of Northwestern University,s Kellogg School of ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Kids Will Pass on 'Healthy' Foods 2
... Chains; 6 Receive an ,F, NEW YORK, Aug. ... your children fat? A year-long study of children,s meals ... sit-down,chain restaurants, according to the authors of the new ... and Matt Goulding calculated,calories, fat (trans- and saturated), and ...
... services for cardiovascular ... ... leader in disease prevention, announced today that the City of Tempe,Arizona ... have asthma or diabetes and are covered under the City,s PPO,Medical ...
... Current strategies can,t beat this growing challenge, researchers say ... of treating tuberculosis are failing in countries with high ... say researchers who analyzed World Health Organization data from ... countries with high rates of MDR-TB, patients are nearly ...
... that builds on healthcare reform proposal, WASHINGTON, ... today by Senators Max Baucus (D-MT) and Kent ... officer of the Blue,Cross and Blue Shield Association ... Senators Baucus and Conrad for introducing legislation that,would ...
... higher risk; doctors urged to expand education efforts , , ... at higher risk for HIV/AIDS, and doctors need to ... tested for HIV. , That,s the new recommendation released ... (ACOG). , "Rates of infection among African Americans ...
... available in <A HREF="http://www.eurekalert.org/pub_releases_ml/2008-08/aaft-t080108.php,">German . , , If someone ... change, but they don,t immediately pull off one of ... leg. With some molecules, however, the situation is quite ... seven atoms. In a charged state, the atoms arrange ...
Cached Medicine News:Health News:America's Worst Restaurants for Kids Revealed 2Health News:America's Worst Restaurants for Kids Revealed 3Health News:America's Worst Restaurants for Kids Revealed 4Health News:America's Worst Restaurants for Kids Revealed 5Health News:City of Tempe, Arizona Extends Contract with U.S. Preventive Medicine for Employee Health Management Program 2Health News:City of Tempe, Arizona Extends Contract with U.S. Preventive Medicine for Employee Health Management Program 3Health News:Drug Resistance Is Slowing Global Fight Against TB 2Health News:BCBSA: Time Is Right for Comparative Effectiveness Research Institute 2Health News:Ob/Gyn Group Urges Routine HIV Tests for All Women 2Health News:Nano sculptures in gold 2Health News:Nano sculptures in gold 3Health News:Nano sculptures in gold 4
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Designated most popular model or size....
Medicine Products: